Introduction
============

Primary liver cancer is the sixth most commonly diagnosed human malignancies and the fourth leading cause of cancer-related death worldwide in 2018, with about 841,000 new cases and 782,000 deaths annually, and hepatocellular carcinoma (HCC) accounts for 75%--80% of primary liver cancer.[@b1-ott-12-1957] Although new therapeutic regimens have been developed in recent years, to date, surgery remains to be the optimal therapeutic choice for HCC. Unfortunately, the prognosis of HCC remains unsatisfactory because of high recurrence and metastasis postsurgery.[@b2-ott-12-1957],[@b3-ott-12-1957] So, to better manage the HCC patients, it has always been important to find proper preoperative clinical and pathological features and markers to predict the prognosis of HCC after surgery.

Since a majority of HCC patients have liver fibrosis or cirrhosis as underlying disease, the residual liver function has been considered as an essential factor in determining the outcomes of HCC patients who underwent curative resection.[@b4-ott-12-1957] Therefore, factors reflecting the residual liver function should be considered as the preferred candidate predictors for the postsurgery overall survival (OS) of HCC patients. Since organ liver plays a fundamental role in lipid metabolism, and alterations of liver function are correlated with modifications of circulating lipids, so the measurement of blood lipid content could be important to evaluate the progression of liver disease.[@b5-ott-12-1957],[@b6-ott-12-1957] Apolipoprotein (Apo), which mainly includes apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB), is a group of serum lipoproteins synthesized in the liver. It has been reported that lower serum ApoA1 level 1 was associated with poor prognosis among HCC patients.[@b7-ott-12-1957] However, whether ApoB is related to the prognosis of HCC patients remains unknown.

ApoB is the main Apo of chylomicron and low-density lipoprotein (LDL). The role of ApoB includes carrying lipids, participating in lipoprotein metabolism, and in the recognition of lipoprotein receptors. ApoB mRNA editing is the deamination of a specific cytidine (nt 6666) to uridine in the ApoB transcript. This deamination results in the formation of an ApoB protein (ApoB48) about one-half the size of the full-length genomically encoded ApoB (apoB100). In humans, the liver synthesizes ApoB100, the major protein component of plasma LDL. The small intestine produces ApoB48, a protein necessary for the secretion of chylomicrons. Lipoproteins containing ApoB48 are rapidly cleared from plasma and are not converted to LDL.[@b8-ott-12-1957],[@b9-ott-12-1957] ApoB100 is the dominating protein in plasma compared with minute amounts of ApoB48 even in the postprandial state. Therefore, ApoB is the nomenclature most often used unless specific studies are performed focusing on ApoB48.[@b10-ott-12-1957] Seventy five percent of LDL combines with LDL receptor (LDLR) through its surface ApoB100 and is cleared by the liver and its peripheral tissue; so, the level of low-density lipoprotein cholesterol (LDL-C) in the serum is closely related to ApoB count. It has been shown that high plasma LDL-C level was associated with poor disease-free survival in patients with breast tumor and advanced stage epithelial ovarian cancers.[@b11-ott-12-1957],[@b12-ott-12-1957] So we wondered whether the serum levels of ApoB and LDL-C could be used to predict the postsurgery survival among HCC patients.

In this study, we mainly explored whether ApoB and LDL-C were independent prognosis predictors of HCC patients after surgical treatment through the use of Cox univariate and multivariate analyses. In the end, the possible mechanism was discussed.

Methods
=======

Study population
----------------

A total of 164 patients who underwent surgical treatment from February 2009 to July 2013 in Henan Cancer Hospital, Zhengzhou, China, were enrolled in this study. The majority of patients were infected with hepatitis B virus (HBV) and they were part of the formal following-up cohort previously reported.[@b4-ott-12-1957],[@b13-ott-12-1957],[@b14-ott-12-1957] In the current study, each enrolled patient met all the following criteria: 1) patients were diagnosed with HCC only, but with no concomitant intrahepatic cholangiocarcinoma, or any other malignancies, to eliminate the confounding effects from disease etiology; 2) patients had ApoB and LDL-C data and the other clinical data possible; 3) patients were successfully followed up until January, 2017; and 4) liver resection was performed on the resectable HCC and none of them received chemotherapy or radiotherapy before the surgery. This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Peking University Health Science Center, Beijing, China. Written informed consents were obtained from all the participants. For patients who were children, written informed consents were obtained from their guardians.

Clinical data collection
------------------------

Data of each patient were collected with the permission of the hospital's ethnic committee, including gender, age at the surgery, cirrhotic status, presence of portal vein tumor thrombus (PVTT), tumor size, HBV (+/−), Barcelona Clinic Liver Cancer (BCLC) stage (A/B/C), and Child--Pugh stage (A/B). The other laboratory data included total bilirubin (T-bil) value, alanine transaminase value, glutamic oxalacetic transaminase or aspartate transaminase (AST) value, alkaline phosphatase (ALP) value, g-glutamyl transpeptidase (GGT) value, albumin (Alb) value, prothrombin time (PT) value, prealbumin (PA) value, total bile acid (TBA) value, ApoA1 value, LDL-C value, very low-density lipoprotein cholesterol value, high-density lipoprotein cholesterol (HDL-C) value, and ApoB value. Only the data from the last examination before surgery were taken into analysis if multiple laboratory tests were performed. In addition, the Child--Pugh grades A--C were determined by the following five assessments: Alb, T-bil, the PT/international normalized ratio, ascites, and hepatic encephalopathy; the BCLC stages were determined by Child--Pugh classification, performance status, and tumor status, and were classified into classes A--D.

Follow-up
---------

The patients were followed up by telephoning or visiting them or their relatives to consult on their physical conditions. The first follow-up was carried out 1 month after hospital discharge when the patients were advised to return to the hospital for a routine examination. The second follow-up was at the end of the third month after surgery. After that, the patients were followed-up every 3 months for the first year, every 6 months for the second and the third year, and once a year for the fourth and the fifth year. We would ask for the exact date of death and the main cause if a patient died during the follow-up. The last case of patient was enrolled in June 2013, the last instance of follow-up was conducted in January 2017. The patients who were alive at the end of the research period were censored.

Statistical analyses
--------------------

The Cox univariate and multivariate analysis models were used to identify the potential independent factors related to survival. The OS rate after surgery was tested by the Kaplan--Meier and the differences among the curves were analyzed using the log-rank analysis; the 1-, 3-, and 5-year survival rates were conducted by Life Tables. Correlations between ApoB and basic clinical data were analyzed using the Spearman's correlation. The associations between the patients' lipid metabolism biomarkers and tumor size were performed by using univariate and multivariate logistic regression. All of the statistical tests were based on a two-sided probability, with a significance level of 0.05, and were performed in SPSS 21.0 (Xishu Software Company, Shanghai, China).

Results
=======

Patient characteristics
-----------------------

The preoperative clinic pathologic data of 164 HCC patients who had undergone curative resection are shown in [Table 1](#t1-ott-12-1957){ref-type="table"}. Among them, 140 (85.4%) of the patients were male and 24 (14.6%) were female; the mean age of the patients was 53 years (range 28--78). Besides, 154 patients (93.9%) had a background of cirrhosis, and HBV infection was the major causative factor of the cohort, with 135 (84.9%) patients were HBV positive. Of all, seven patients were lost during the follow-up visit. Therefore, the OS analysis was performed and the prognosis predicting values of ApoB and other 21 clinical variables were evaluated in the remaining 157 patients who were successfully followed-up.

Identification of the independent risk factors for poor prognosis in HCC patients who underwent surgical treatment
------------------------------------------------------------------------------------------------------------------

To investigate the risk factors for poor prognosis after surgical treatment, the preoperative ApoB and LDL-C levels, as well as other 19 potential clinical variables, were analyzed by univariate analysis. As shown in [Table 2](#t2-ott-12-1957){ref-type="table"}, ApoB as well as tumor size, tumor number, PVTT, BCLC, AST, ALP, GGT, and Alb were identified as the candidate risk factors for poor prognosis. Further multivariate analysis through Cox proportional hazards model identified that elevated ApoB level, advanced BCLC stage, and lower Alb level were the independent risk factors for poor prognosis in patients with HCC after surgical treatment ([Table 3](#t3-ott-12-1957){ref-type="table"}). Unlike in patients with breast tumor or epithelial ovarian cancers,[@b11-ott-12-1957],[@b12-ott-12-1957] level of LDL-C exhibited no prognosis correlation in HCC patients, at least in this cohort.

Elevated ApoB was associated with worse prognosis in HCC patients
-----------------------------------------------------------------

According to the normal reference range of ApoB level (0.8--1.05 g/L), the patients were divided into three groups based on each patient's preoperative ApoB measurement: group 1 was composed of patients with ApoB level \<0.8 g/L, group 2 was composed of patients with ApoB falling in the normal reference range, while group 3 was composed of patients with ApoB level \>1.05 g/L. Kaplan--Meier curves for OS rate of patients in three groups are plotted in [Figure 1](#f1-ott-12-1957){ref-type="fig"}. The OS of the patients in group 3 was significantly poorer than that of the patients in group 1 (*P*=0.015). The median survival time in three groups was 22.4, 15.5, and 6.03 months, respectively, and the survival time in group 3 is much shorter than in group 1 (*P*=0.015). In concordance, the 1-, 3-, and 5-year survival rates of patients in group 1 were 66%, 40%, and 29%, respectively, which were much higher than the respective OS rates of 36%, 24%, and 15% in group 3 (*P*=0.018). However, the 1-, 3-, and 5-year survival rates of patients in group 2 were 57%, 28%, and 21%, which has no statistical difference with group 1 (*P*=0.249) and group 3 (*P*=0.125).

Correlations between ApoB and other basic clinical variables
------------------------------------------------------------

In order to explore the relationship between ApoB and other clinical variables, the bivariate correlations were conducted. As shown in [Table 4](#t4-ott-12-1957){ref-type="table"}, the preoperative ApoB was observed to be associated with tumor size and LDL-C, the correlation coefficient between ApoB and LDL-C was noticeably high (*r*=0.686, *P*\<0.001). It was worthwhile to notice that HCC patients with higher ApoB level were also more likely to have higher ALP, α-fetoprotein (AFP), GGT, but had nothing to do with the Child--Pugh score ([Table 4](#t4-ott-12-1957){ref-type="table"}).

Elevated ApoB was a predictive factor for tumor size ≥5 cm at diagnosis
-----------------------------------------------------------------------

We noticed from [Figure 2](#f2-ott-12-1957){ref-type="fig"} that the significant increase in tumor sizes was in parallel with the elevated ApoB level in the serum. In other words, patients in group 3 had tumor larger in size when compared with that in group 1 (*P*\<0.001) and group 2 (*P*=0.006). To further validate such associations between tumor size and the quantification of patients' lipid metabolism biomarkers, univariate and multivariate logistic regression analysis was performed. The result showed that gender, ApoB, and ApoA1 are independent predictor factors for tumor size ≥5 cm at diagnosis. The patients who had higher ApoB level were more likely to have the tumor size ≥5 cm, with the OR value as high as 2.221 (95% CI: 1.288--3.830, *P*=0.004). Conversely, the patients who had higher ApoA1 count were less likely to have the tumor size ≥5 cm, with the OR value of 0.430 (95% CI: 0.219--0.844, *P*=0.014). ([Table 5](#t5-ott-12-1957){ref-type="table"}).

Discussion
==========

The outcome of a patient after receiving certain treatment is of importance when a therapeutic strategy has to be recommended. In addition to tumor-related factors, including tumor size, number of tumors, vascular invasion, and AFP,[@b14-ott-12-1957]--[@b17-ott-12-1957] as well as p53 mutation reported by us and others,[@b18-ott-12-1957] the poor outcome of HCC could also be attributed to the factor, which influenced the basic function of residual liver after curative surgical treatment. Therefore, for the proper management of HCC patients, a practicable and effective prognostic factor with higher accuracy is extremely needed.

Liver plays a fundamental role in lipid metabolism and is thought to be the major assembled center for the production of most endogenous lipids, Apos, and lipoproteins. Recently, abnormal lipid metabolism has been validated to be a vital metabolic reprogramming process in cancer cells,[@b19-ott-12-1957] and the majority of researches about the relationship between LDL-C and cancer are concentrated in breast cancer. One article suggested that LDL-C levels at diagnosis emerged as a prognostic factor in breast cancer patients and patients with high levels of LDL-C at diagnosis had reduced DFS, which was favored by the strong association of LDL-C level and tumor size before treatment.[@b11-ott-12-1957] Another published data supported the notion that cancer cells were able to uptake cholesterol from the bloodstream, for example, plasma LDL-C could be used by cancer cells. Also, preoperative ApoB/ApoA1 ratio has been found to be a novel prognostic factor for gastric cancer.[@b20-ott-12-1957] As it has been reported in the literature that low level of ApoA1 is associated with poor prognosis in HCC patients,[@b7-ott-12-1957] our article mainly tested whether ApoB, LDL-C, and HDL-C were independent prognosis predictors of HCC patients.

In our results, we identified that tumor size, tumor number, PVTT, BCLC stage, AST, ALP, GGT, Alb, PA, ApoA1, and ApoB were the risk factors for poor prognosis in patients with HCC after surgical treatment through Cox univariate analysis ([Table 2](#t2-ott-12-1957){ref-type="table"}). In order to select the independent predictors for postsurgery prognosis of HCC patients, further Cox multivariate analysis was conducted, and the result showed that BCLC stages, Alb, and ApoB were significant predictors ([Table 3](#t3-ott-12-1957){ref-type="table"}). LDL-C level at diagnosis has been suggested as a prognostic factor in breast cancer patients.[@b11-ott-12-1957] However, it exhibited no prognostic correlation in HCC patients, at least in this cohort. As ApoB was related to LDL-C, with correlation coefficient between them as high as 0.686 (*P*\<0.001), the relationship between LDL-C and cancer has been reported in several articles[@b12-ott-12-1957],[@b21-ott-12-1957] and some metabolic-related index, such as LDL-C was found to be closely related to cancer cells.[@b22-ott-12-1957]--[@b24-ott-12-1957] So, we could speculate that tumors might grow rapidly in the high ApoB group, which is consistent with the correlation between ApoB and tumor size in our result (*r*=0.355, *P*\<0.001). To validate the associations between the patients' lipid metabolism biomarkers and tumor size, further analysis was performed using univariate and multivariate logistic regression. The result showed that gender, ApoB, and ApoA1 are independent predictor factors for tumor size ≥5 cm at diagnosis. The patients who had higher ApoB level were more likely to have the tumor size ≥5 cm, with the OR value as high as 2.221 (95% CI: 1.288--3.830, *P*=0.004). Conversely, the patients who had higher ApoA1 count were less likely to have the tumor size ≥5 cm, with the OR value of 0.430 (95% CI: 0.219--0.844, *P*=0.014). It has been proved that ApoA1 can inhibit tumor cell proliferation, induce apoptosis, and impair their extracellular matrix degradation.[@b7-ott-12-1957] So, we could speculate that ApoB might be related to the tumor growth.

We noticed that Lee et al[@b25-ott-12-1957] reported that ApoB might play a role in regulating multiple genes involved in HCC development, and ablation of APOB in tumor tissues was significantly associated with poor clinical outcome in HCC patients and increased proliferation of HCC cells. Differently, Lin et al[@b26-ott-12-1957] showed that ApoB was not an independent risk factor for HCC development in their cohort. As we know, besides malignancy of the tumor tissue, the residual liver function could also affect the HCC patient's outcome. ApoB is synthesized and degraded in the liver, the content of ApoB in serum is related not only to the speed of synthesis but also to the state of degradation. ApoB is a major constitutive protein of LDL and VLDL. Triglycerides, ApoB100, and cholesterol are assembled into VLDL after liver synthesis and then secreted into the blood circulation. The lipoprotein esterase attached to the vessel wall breaks down the triglycerides of VLDL into free fatty acids and glycerol, providing energy to peripheral tissues. In this process, VLDL is transformed to intermediate-density lipoprotein and LDL, LDL combines with LDLR through ApoB100 on its surface and ApoB100 is broken down into amino acids in the liver for the next cycle. We speculated that the elevated ApoB level in the serum reflected the reduced expression of LDLR, and the poor postoperative prognosis might be associated with the poor residual liver function.

To the best of our knowledge, this is the first report to discover the clinical significance of serum ApoB levels for predicting the postoperative prognosis of HCC patients. Of course, there are some limitations in our study. For instance, as the sample size is not very large and the data are collected from a single hospital, the representation of our result is limited. Besides, the majority of patients in our cohort have the background of HBV infection, so the results are more suitable for HBV-related HCC patients. As a result, the aforementioned result obtained through this observation study need to be confirmed in the future with multicenter cohort studies and the underlying mechanism relevant to ApoB's effect on the overall postoperative survival of HCC patients also need to be studied. Since the measurement of ApoB is becoming common in clinical practice and the lipoprotein metabolism could be an important therapeutic target in HCC patients, we expect that more data will be generated and eventually clear the potential use of ApoB in the management of HCC patients with tumors \>5 cm.

Conclusion
==========

ApoB could be a valuable novel prognosis predicting marker for HCC patients who underwent curative liver resection. And elevated ApoB level in serum could indicate worse outcome in HCC patients, which could be explained by the relationship between ApoB and residual liver function.
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![Comparison of overall survival rate among patients in three groups.\
**Notes:** Group 1: patients with ApoB \<0.8 g/L (n=85); group 2: patients with the ApoB level between 0.8 and 1.05 g/L (n=47); group 3: patients with the ApoB level \>1.05 g/L (n=25). Log-rank test: group 1 vs 2, *P*=0.226; group 2 vs 3, *P*=0.193; group 1 vs 3, *P*=0.015.](ott-12-1957Fig1){#f1-ott-12-1957}

![Comparison of tumor size among patients in three groups.\
**Note:** Group 1: patients with ApoB \<0.8 g/L (n=89); group 2: patients with ApoB between 0.8 and 1.05 g/L (n=48); group 3: patients with ApoB \>1.05 g/L (n=27).\
**Abbreviation:** ApoB, apolipoprotein B.](ott-12-1957Fig2){#f2-ott-12-1957}

###### 

Characteristics of 164 HCC patients before the surgery

  Variables                                  N          Mean ± SD
  ------------------------------------------ ---------- ---------------
  Gender (male/female)                       140/24     --
  Cirrhosis (+/−)                            154/9      --
  PVTT (+/−)                                 44/117     --
  HBV (+/−)                                  135/24     --
  BCLC (A/B/C)                               72/33/55   --
  Child--Pugh (A/B)                          145/18     --
  Age (≤60/\>60, years)                      130/34     52.82±10.187
  Tumor size (≤5/\>5, cm)                    48/116     9.26±4.76
  AFP (≤400/\>400, ng/μL)                    79/82      588.50±549.47
  GGT (\<7/7--50/\>50, U/L)                  0/39/125   161.06±159.56
  ALT (\<5/5--40/\>40, U/L)                  0/72/92    59.71±64.19
  AST (\<8/8--40/\>40, U/L)                  0/45/119   76.99±63.73
  ALP (\<40/40--150/\>150, U/L)              0/122/42   130±82.55
  Alb (\<34/34--48/\>48, g/L)                24/137/3   39.35±5.95
  PA (\<200/200--400/\>400, mg/L)            128/24/0   142.47±55.51
  PT (\<11/11--14.3/\>14.3, s)               6/111/47   13.53±1.66
  ApoA1 (\<1.2/1.2--1.6/\>1.6, g/L)          119/41/4   0.98±0.32
  ApoB (\<0.8/0.8--1.05/\>1.05, g/L)         89/48/27   0.81±0.32
  LDL-C (\<2.07/2.07--3.12/\>3.12, mmol/L)   37/82/45   2.81±1.07
  HDL-C (≤1.02/\>1.02, mmol/L)               57/107     1.20±0.45
  Cholesterol (≤5.17/\>5.17, mmol/L)         134/30     4.35±1.11
  TBA (≤9.67/\>9.67, μmol/L)                 55/95      19.78±23.96

**Abbreviations:** AFP, α-fetoprotein; ALP, alkaline phosphatase; ALT, alanine amino transferase; AST, aspartate transaminase; Alb, albumin; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BCLC, Barcelona Clinic Liver Cancer; GGT, g-glutamyl transpeptidase; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PA, prealbumin; PT, prothrombin time; PVTT, portal vein tumor thrombus; TBA, total bile acid.

###### 

Univariate Cox proportional hazard model for predictors of death

  Variables                                  β        HR      95% CI         *P*-value
  ------------------------------------------ -------- ------- -------------- -----------
  Gender (male/female)                       −0.279   0.757   0.440--1.300   0.312
  Age (≤60/\>60, years)                      0.101    1.107   0.716--1.710   0.647
  Cirrhosis (+/−)                            −0.360   0.698   0.324--1.501   0.357
  Tumor size (≤5/5, cm)                      0.495    1.641   1.089--2.473   0.018
  Tumor number (1/≥2)                        0.800    2.225   1.549--3.198   \<0.001
  PVTT                                       −0.764   0.466   0.314--0.691   \<0.001
  Child--Pugh (A/B)                          0.294    1.341   0.780--2.305   0.288
  BCLC (A/B/C)                               0.391    1.478   1.211--1.804   \<0.001
  AFP (≤400/\>400, ng/μL)                    0.212    1.237   0.862--1.775   0.249
  ALT (≤40/\>40, U/L)                        0.089    1.093   0.762--1.569   0.628
  AST (≤40/\>40, U/L)                        0.454    1.574   1.036--2.391   0.034
  ALP (≤150/\>150, U/L)                      0.583    1.791   1.206--2.660   0.004
  GGT (≤50/\>50, U/L)                        0.443    1.557   1.008--2.405   0.046
  PT (\<11/11--14.3/\>14.3, s)               0.305    1.357   0.953--1.933   0.091
  Alb (\<34/34--48/\>48, g/L)                −0.705   0.494   0.317--0.771   0.002
  PA (≤200/\>200, mg/L)                      −0.531   0.588   0.323--1.071   0.083
  ApoA1 (\<1.2/1.2--1.6/\>1.6, g/L)          −0.230   0.794   0.550--1.148   0.221
  HDL-C (≤1.02/\>1.02, mmol/L)               −0.157   0.855   0.589--1.242   0.411
  ApoB (\<0.8/0.8--1.05/\>1.05, g/L)         0.295    1.343   1.060--1.701   0.015
  LDL-C (\<2.07/2.07--3.12/\>3.12, mmol/L)   0.180    1.198   0.922--1.556   0.177
  TBA (≤9.67/\>9.67, μmol/L)                 −0.072   0.930   0.637--1.359   0.708

**Abbreviations:** AFP, α-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate transaminase; Alb, albumin; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BCLC, Barcelona Clinic Liver Cancer; GGT, g-glutamyl transpeptidase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PA, prealbumin; PT, prothrombin time; PVTT, portal vein tumor thrombus; TBA, total bile acid.

###### 

Multivariate Cox proportional hazard model for predictors of death

  Variables                            β        HR      95% CI         *P*-value
  ------------------------------------ -------- ------- -------------- -----------
  BCLC (A/B/C)                         1.279    3.595   2.237--5.776   \<0.001
  Alb (\<34/34--48/\>48, g/L)          −1.190   0.304   0.165--0.563   \<0.001
  ApoB (\<0.8/0.8--1.05/\>1.05, g/L)   0.333    1.396   1.026--1.898   0.033

**Abbreviations:** Alb, albumin; ApoB, apolipoprotein B; BCLC, Barcelona Clinic Liver Cancer.

###### 

Correlations between ApoB and clinicopathological characteristics

  Variables           ApoB     
  ------------------- -------- ---------
  ALT (U/L)           −0.053   0.502
  AST (U/L)           0.070    0.372
  Tumor size (cm)     0.355    \<0.001
  AFP (ng/μL)         0.169    0.032
  ALP (U/L)           0.232    0.003
  GGT (U/L)           0.260    0.001
  HDL-C (mmol/L)      −0.086   0.271
  LDL-C (mmol/L)      0.686    \<0.001
  PA (mg/L)           0.082    0.314
  Child--Pugh (A/B)   0.056    0.479

**Abbreviations:** AFP, α-fetoprotein; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate transaminase; ApoB, apolipoprotein B; GGT, g-glutamyl transpeptidase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PA, prealbumin; *r*, correlation coefficient.

###### 

Univariate and multivariate logistic regression to the risk of tumor size ≥5 cm

  Variables                                  Univariate analysis   Multivariate analysis                                  
  ------------------------------------------ --------------------- ----------------------- ------- ------- -------------- -------
  Gender (female/male)                       2.889                 1.192--7.002            0.019   3.060   1.195--7.838   0.020
  ApoB (\<0.8/0.8--1.05/\>1.05, g/L)         2.019                 1.198--3.403            0.008   2.221   1.288--3.830   0.004
  ApoA1 (\<1.2/1.2--1.6/\>1.6, g/L)          0.490                 0.260--0.926            0.028   0.430   0.219--0.844   0.014
  HDL-C (≤1.02/\>1.02, mmol/L)               0.801                 0.391--1.642            0.545                          
  LDL-C (\<2.07/2.07--3.12/\>3.12, mmol/L)   1.651                 1.012--2.694            0.045                          
  Age (≤60/\>60, years)                      0.506                 0.230--1.112            0.090                          

**Abbreviations:** ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
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